Intco Medical Technology Stock: Fair Value
300677.SZThe fair value of Intco Medical Technology under our model is $8.00, the price is 10% below.
The fair value is an estimate from our model, not a price target.
Daily figure as of 20 Nov 2026
Valuation Signal
Fairly valuedClosing price of 19 Nov 2026, used by the daily score.
In our model the price counts as cheap below $5.72 and expensive above $13.34 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 7.9%. At 8.9% the fair value would be $6.63, at 6.9% it would be $9.98.
Where the Number Comes From
From the cash-flow model alone; after a one-off collapse in earnings there is no industry value.
Ten-year cash-flow model: 3 years from analyst estimates, then extrapolated until growth reaches 2.3% (five-year average government bond yield). Discounted at 7.9% (government bond yield 2.3% plus beta 1.09 times a risk premium of 5.2%).
Calculate with your own assumptionsThe Calculation Step by Step
With these figures the cash flow model arrives at $8.00 per share: free cash flow for the next ten years, each year discounted to today at 7.9%, plus the terminal value for the years after. The table explains the calculation; it is not a recommendation.
Calculation as a table
| Year | Free cash flow | Source | Discount factor | Present value (discounted at 7.9%) |
|---|---|---|---|---|
| 2026 | −$105.72M | Estimate, 3 analysts | 0.9266 | −$97.96M |
| 2027 | $109.47M | Estimate, 3 analysts | 0.8585 | $93.99M |
| 2028 | $264.39M | Estimate, 3 analysts | 0.7955 | $210.32M |
| 2029 | $294.75M | extrapolated at 11.5% | 0.7371 | $217.26M |
| 2030 | $320.48M | extrapolated at 8.7% | 0.6830 | $218.88M |
| 2031 | $342.29M | extrapolated at 6.8% | 0.6328 | $216.61M |
| 2032 | $360.96M | extrapolated at 5.5% | 0.5864 | $211.66M |
| 2033 | $377.25M | extrapolated at 4.5% | 0.5433 | $204.97M |
| 2034 | $391.78M | extrapolated at 3.9% | 0.5034 | $197.24M |
| 2035 | $405.06M | extrapolated at 3.4% | 0.4665 | $188.95M |
| Step | Value |
|---|---|
| Sum of present values (ten years) | $1.66B |
| Terminal value: cash flow 2035 × (1 + 2.3%) / (7.9% − 2.3%) | $7.38B |
| Present value of terminal value (× 0.4665) | $3.44B |
| Equity value (sum plus present value of terminal value) | $5.11B |
| Shares (diluted) | 637.94M |
| Value per share (equity value divided by shares) | $8.00 |
| Fair value (from the cash flow model alone) | $8.00 |
In the years with estimates, the model derives free cash flow from estimated earnings and revenue, because there are no estimates for the cash flow itself. The model uses free cash flow after interest, which belongs to shareholders, discounted at the cost of equity. Net debt is therefore not deducted again.
Data and Required Disclosures
- ; time horizon around 12 months
- Rated Weak since 7 Nov 2026; valuation signal Fairly valued since 20 Nov 2026
- Price: closing price of 20 Nov 2026
- Amounts in US dollars at the ECB reference rate of 19 Nov 2026 ($1 = CN¥6.6667)
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2025. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
